An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer

Part of paid clinical trials in Duarte, California.

Sponsor
Bristol-Myers Squibb
Study ID
NCT02750514
Phase
PHASE2
Status
Terminated

Conditions

  • Advanced Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — BIOLOGICAL
    Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator.
  • Dasatinib — DRUG
  • Relatlimab — BIOLOGICAL
  • Ipilimumab — BIOLOGICAL
  • BMS-986205 — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to determine whether Nivolumab, in combination with other therapies, is effective in patients with advanced Non-Small Cell lung cancer

Key Dates

Start date
May 9, 2016
Status verified
Feb 2021
Primary completion
Jan 29, 2020
Completion
Jan 29, 2020

Study Design

Enrollment
295 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Nivolumab
    Nivolumab Monotherapy - Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator
  • Experimental: Nivolumab & Dasatinib
    Nivolumab in combination with Dasatinib
  • Experimental: Nivolumab & Relatlimab
    Nivolumab in combination with Relatlimab
  • Experimental: Nivolumab & Ipilimumab
    Nivolumab in combination with Ipilimumab
  • Experimental: Nivolumab & BMS-986205
    Nivolumab in combination with BMS- 986205

Primary Outcome Measure

Objective Response Rate (ORR) [ Time Frame: From first dose to 2 years following last dose (up to 30 months) ]

Locations (35)

FacilityCityStateZIPSite coordinators
City of Hope National Medical CenterDuarteCalifornia91010-
Cedars-Sinai Medical CenterLos AngelesCalifornia90048-
University of Californa, Los Angeles (UCLA)Los AngelesCalifornia90095-
University of Southern California (USC)Los AngelesCalifornia90033-
Hoag Memorial Hospital PresbyterianNewport BeachCalifornia92658-
University of California San DiegoSan DiegoCalifornia92122-
University of Colorado DenverAuroraColorado80045-
Yale Cancer CenterNew HavenConnecticut06511-
University of Kansas Cancer CenterWestwoodKansas66205-
Sidney Kimmel Comprehensive Cancer CenterBaltimoreMaryland21287-
University of Maryland - Marlene and Stewart Greenebaum Cancer CenterBaltimoreMaryland21201-
Beth Israel Deaconess Medical CenterBostonMassachusetts02215-
Dana Farber/Harvard Cancer CenterBostonMassachusetts02215-
Massachusetts General HospitalBostonMassachusetts02114-
University of Michigan Health System (UMHS) - University Hospital (University of Michigan Medical CeAnn ArborMichigan48109-
Karmanos Cancer InstituteDetroitMichigan48201-
Washington University, The Center for Advanced MedicineSt LouisMissouri63110-
Comprehensive Cancer Centers of NevadaLas VegasNevada89119-
Roswell Park Cancer InstituteBuffaloNew York14263-
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065-
Univ of NC Shool of MedicineChapel HillNorth Carolina27514-
The Ohio State UniversityColumbusOhio43210-
Northwest Cancer SpecialistsPortlandOregon97225-
Fox Chase Cancer CenterPhiladelphiaPennsylvania19111-2497-
Thomas Jefferson UniversityPhiladelphiaPennsylvania19107-
University of Pittsburgh Medical CenterPittsburghPennsylvania15217-
The West Clinic, P.C. d/b/a West Cancer CenterGermantownTennessee38138-
Sarah Cannon Cancer CenterNashvilleTennessee37203-
Sammons Cancer Center (Uso)DallasTexas75246-
Texas Oncology, P.A.Fort WorthTexas76104-
The University of Texas MD Anderson Cancer CenterHoustonTexas77030-
Us OncologyTylerTexas75702-
Huntsman Cancer InstituteSalt Lake CityUtah84112-
Virginia Cancer Specialists, PCFairfaxVirginia22031-
University of Washington-Seattle Cancer Care AllianceSeattleWashington98109-

Find similar trials in Duarte, CA

Related Studies